For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
The July 2016 issue of MedicinMan with articles by Piyush Agarwal, K. Hariram, Vivek Hattangadi, Anjali Sharma, Chandan Kumar, RB Balakrishna and Pankaj Mehrotra
Special interview with the Chairman of ACG and an invitation to "Pharmaceutical Marketing in the New Age" - a conference presented by ACG in partnership with MedicinMan
Arun Subramanian is a Co-founder & Head of Sales Enablement at Enparadigm. Arun and his team are building sharpsell.ai - a Sales Enablement and Learning platform that equips distributed field sales teams with ready-to-use product pitches, dynamic personalized content, and AI-powered coaching to help reps make compelling sales pitches and drive productivity.
Challenging times lay ahead for the sales departments in the pharma industry. The COVID-19 pandemic will surely not be the first disruption, as recent geopolitical tensions, and economic turmoil show. Agile and adaptive sales enablement is thus a must-have in the coming months and years.